Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

NCT: NCT02928497 · TERMINATED

NCT IDNCT02928497
StatusTERMINATED
Start Date2017-02-06
Completion2025-09-23
SponsorBoston Scientific Corporation (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑